Hogan Lovells advises Gilead Sciences on its collaboration with Goldfinch Bio to develop novel therapies for kidney disease
New York, 8 May 2019 – A team from Hogan Lovells has advised Gilead Sciences on a partnership with Goldfinch Bio, a biotechnology company focused on developing precision therapies for patients with kidney diseases.
The strategic collaboration will help to discover, develop and commercialize a pipeline of innovative therapeutics for diabetic kidney disease (DKD) and certain orphan kidney diseases.
The Hogan Lovells team advising Gilead Sciences was led by Adam Golden (partner) and Anishiya Abrol (counsel), with support from Katherine McGuigan (associate) and Katherine Jeffrey (associate).
About Hogan Lovells
Hogan Lovells is a leading global legal practice providing business-oriented legal advice and high-quality service across its exceptional breadth of practices to clients around the world.
"Hogan Lovells" or the "firm" is an international legal practice that includes Hogan Lovells US LLP and Hogan Lovells International LLP. For more information, see www.hoganlovells.com.
###